
- /
- Supported exchanges
- / US
- / BLUE.NASDAQ
Bluebird bio Inc (BLUE NASDAQ) stock market data APIs
Bluebird bio Inc Financial Data Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bluebird bio Inc data using free add-ons & libraries
Get Bluebird bio Inc Fundamental Data
Bluebird bio Inc Fundamental data includes:
- Net Revenue: 83 807 K
- EBITDA: -206 455 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bluebird bio Inc News

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions bl...


CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
Despite my optimism about the long-term prospects of curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a sense of pragmatism and potentially a reality check are in order. Noting the n...

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothin...

BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Last week, Bluebird Bio (NASDAQ:BLUE) shares climbed while CRISPR Therapeutics (NASDAQ:CRSP) stock fell back. The latter has since spiked, while Bluebird Bio has given back many of its gains from the ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.